Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. (NYSE: GEHC) is a leading global innovator in medical technology, pharmaceutical diagnostics, and digital solutions. The company operates through four main segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Of these, the Imaging segment generates the majority of the company’s revenue.
GE HealthCare is dedicated to providing transformational medical technologies and services that enhance access to quality, affordable healthcare worldwide. Through its cutting-edge products and comprehensive solutions, the company aims to improve patient outcomes and streamline healthcare delivery.
Recent achievements include advancements in artificial intelligence (AI) integration within medical imaging, which supports more accurate and efficient diagnostics. The company is also involved in numerous partnerships with healthcare providers and research institutions to drive innovation and improve global healthcare standards.
Financially, GE HealthCare has showcased robust performance, with steady revenue growth and strong market presence. The company continuously invests in R&D to maintain its edge in the competitive healthcare industry. Their suite of products includes advanced imaging machines, ultrasound devices, patient monitoring systems, and contrast media for diagnostic imaging.
As part of a highly regulated industry, GE HealthCare adheres to strict compliance standards and maintains rigorous quality controls across its operations. The company actively engages with its community, although it reserves the right to monitor and manage public interactions to uphold professional and constructive discourse.
GE HealthCare (Nasdaq: GEHC) announced FDA approval of Flyrcado (flurpiridaz F 18) injection, a novel PET radiotracer for detecting coronary artery disease (CAD). Flyrcado offers higher diagnostic efficacy compared to SPECT MPI, the current standard in nuclear cardiology. With a 109-minute half-life, it allows for off-site production and wider distribution, potentially expanding access to PET myocardial perfusion imaging (MPI).
Key advantages include:
- First practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD
- Improved diagnostic accuracy for difficult-to-image patients
- Ability to rescan patients during the same session if needed
GE HealthCare (Nasdaq: GEHC) announced its latest innovations in radiation oncology to be showcased at the American Society for Radiation Oncology (ASTRO) 2024 conference. The company is presenting several AI-enhanced solutions aimed at improving the radiation therapy workflow:
1. Intelligent Radiation Therapy (iRT): Enables multi-vendor system interoperability and efficiency throughout the care continuum.
2. Revolution™ RT: A wide-bore CT platform for precision radiation therapy simulation.
3. MIM Maestro and Contour ProtégéAI+: Interoperable technologies for AI auto-contouring and improved treatment planning.
4. Prostate Volume Assist: AI software for automated prostate volume measurements.
5. StarGuide™: A digital SPECT/CT system for personalized care decisions in Theranostics.
These innovations aim to streamline workflows, reduce time to treatment, and improve patient outcomes in radiation oncology.
GE HealthCare (Nasdaq: GEHC) has unveiled enhanced Venue ultrasound systems and introduced Venue Sprint, a new portable ultrasound device for point-of-care (POCUS) applications. Venue Sprint combines powerful Venue software, AI-enabled tools, and wireless probe capability with Vscan Air handheld systems. The Venue family now offers wireless probe connectivity, advanced clinical tools, and ViewPoint 6 updates for improved efficiency.
Key features of Venue Sprint include:
- Tablet form factor for maximum portability
- Wireless Vscan Air dual-probes for flexible use
- AI-enabled resources and documentation tools
- Integration with Caption Guidance for cardiac ultrasound imaging
These innovations aim to empower clinicians to deliver care in various settings, potentially reducing health inequities and expanding access across different care areas.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a cash dividend for the third quarter of 2024. The company's Board of Directors has declared a dividend of $0.03 per share of Common Stock. This dividend will be payable on November 15, 2024 to all shareholders of record as of October 18, 2024. This announcement demonstrates GE HealthCare's commitment to providing regular returns to its shareholders, albeit at a modest level.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) has priced its upsized secondary public offering of 15,000,000 shares of common stock at $86.00 per share. The offering was increased from the initially announced 10,000,000 shares. GE HealthCare will not receive any proceeds from the sale. Prior to closing, GE Aerospace is expected to exchange the shares for debt held by Morgan Stanley affiliates. The selling stockholder has granted underwriters an option to purchase an additional 2,250,000 shares. Morgan Stanley and Citigroup are leading the offering, which is expected to close on September 16, 2024, subject to customary conditions.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) has announced a secondary public offering of 10,000,000 shares of its common stock. The company itself is not selling any shares or receiving proceeds from the sale. Prior to the offering's closing, GE Aerospace is expected to exchange the GEHC shares for debt held by Morgan Stanley affiliates. The selling stockholder has granted underwriters an option to purchase an additional 1,500,000 shares for settlement by September 30, 2024. Morgan Stanley and Citigroup are acting as lead joint book-running managers for the offering. The company has filed an automatically effective shelf registration statement with the SEC for this offering.
GE HealthCare (Nasdaq: GEHC) announced CE marks for two innovative cardiology solutions: the Vscan Air™ SL with Caption AI™, an AI-driven handheld ultrasound system for rapid cardiac assessments, and ECG-less Cardiac CT scanning on its Revolution Apex™ platform. These technologies aim to enable more efficient and timely cardiac care at the point of service.
The Vscan Air SL with Caption AI provides real-time guidance for capturing cardiac images, even for non-experts, and includes an AutoEF feature for calculating left ventricular ejection fraction. The ECG-less Cardiac CT solution allows for cardiac imaging without an ECG signal, prioritizing patient access and speed.
Both innovations will be showcased at the European Society of Cardiology (ESC) Congress in London, August 30-September 2, 2024, along with GE HealthCare's Allia™ IGS 5 Pulse image-guided platform for interventional cardiology.
GE HealthCare (Nasdaq: GEHC) has announced its management's participation in two upcoming investor conferences in September 2024. The company will be presenting at the 2024 Wells Fargo Healthcare Conference in Boston on September 4 at 10:15 am ET, and the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on September 5 at 1:05 pm ET.
Investors and interested parties can access these presentations through the GE HealthCare Investor Relations website. This announcement highlights the company's commitment to engaging with investors and sharing insights about its operations and future prospects in the healthcare industry.
GE HealthCare (Nasdaq: GEHC) announced the publication of the MASTER trial results in Anesthesia and Analgesia, demonstrating the safety and efficacy of End-tidal Control software for inhaled anesthetic administration. The study, conducted across four U.S. hospitals with 210 adult patients, showed that End-tidal Control achieved:
- Targeted end-tidal anesthetic concentrations within 5% of the set value 98% of the time, compared to 46% with manual control
- Targeted end-tidal oxygen concentrations within 5% of the set value 86% of the time, versus 41% with manual control
- Faster response times for achieving 90% of the initial desired end-tidal anesthetic concentration (median 75 seconds vs. 158 seconds)
The software also demonstrated potential to reduce anesthetic agent usage, greenhouse gas emissions, and costs compared to manual control.
GE HealthCare has announced a collaboration with the University of California San Diego School of Medicine to develop advanced MRI protocols and educational materials for women's pelvic imaging. The project, led by Dr. Rebecca Rakow-Penner, aims to improve diagnosis and management of female pelvic diseases such as endometriosis and ovarian cancer. This initiative addresses the gap in medical research and care for women's pelvic health, which is often understudied and misdiagnosed.
The collaboration seeks to democratize advanced imaging for women and increase access to high-quality care. By creating training materials and protocols, the project aims to equip clinicians worldwide with tools to deliver better care. This could potentially improve patient experiences and help clinicians make more informed decisions, ultimately bridging an important gap in women's healthcare.
FAQ
What is the current stock price of GE HealthCare Technologies (GEHC)?
What is the market cap of GE HealthCare Technologies (GEHC)?
What does GE HealthCare Technologies Inc. do?
What are the main business segments of GE HealthCare?
How does GE HealthCare generate most of its revenue?
What recent advancements has GE HealthCare made?
Who are GE HealthCare's partners?
How does GE HealthCare ensure compliance?
What products does GE HealthCare offer?
What is GE HealthCare's commitment to the community?
How has GE HealthCare performed financially?
What is GE HealthCare's mission?
